Background: Population-based survival data is commonly used to evaluate the effectiveness of cancer prevention and treatment. This study aims to assess the 5-year relative survival of patients with cancer in Fujian Province, southeastern China, between 2021 and 2023.
Methods: The new cases of cancer in 25 cancer registries in Fujian Province from 2016 to 2021 were included in this study, and patients' survival status was followed up until March 1, 2024. The hybrid method was used to calculate cancer relative survival by gender, region and age (2021-2023), and results were standardized according to International Cancer Survival Standards Weights.
Results: There were 184,216 patients were included in the study after quality control, including 101,338 males and 82,878 females. The 5-year relative survival for all cancers combined was 51.7 %, and the age-standardized 5-year relative survival was 43.8 % in 2021-2023. The age-standardized 5-year relative survival was higher in females than males (52.7 % and 36.3 %). The survival in urban was higher than that in rural areas (49.3 % and 37.9 %). The three types of cancer with the highest survival in males were thyroid (94.5 %), testicular (77.7 %), bladder (69.1 %). In females, thyroid cancer (94.9 %), breast cancer (77.6 %) and bladder cancer (72.1 %) were the three cancers with the highest survival. Most cancer survival was higher in females than in males. The relative survival decreased with age, the highest survival was 79.5 % in the age group under 45 years old and the lowest survival was 21.8 % in the age 75 and above.
Conclusions: The cancer survival rates in Fujian Province have reached the goal of Healthy China 2030, but there is still a gap with high survival areas. To narrow this gap, more targeted interventions are needed to further improve cancer survival.
Keywords: Cancer; Cancer registry; Population-based; Relative survival.
Copyright © 2025. Published by Elsevier Ltd.